Expertise in
39
conditions

Dr. Darla K. Liles

Hematology
Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center
524 Moye Blvd, 
Greenville, NC 
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center
524 Moye Blvd, 
Greenville, NC 

Overview

Darla Liles is a Hematologist practicing medicine in Greenville, North Carolina.

Dr. Liles is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Autoimmune Hemolytic Anemia, Bone Marrow Aspiration, and Fasciotomy.

She is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 32 clinical trials. Dr. Liles is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NC

Hospital Affiliations

Ecu Health Medical Center
The Outer Banks Hospital, Inc
Vidant Roanoke Chowan Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center
524 Moye Blvd, Greenville, NC 27834
Other Locations
ECU Health Beaufort Hospital, a Campus of ECU Health Medical Center
628 E 12th St, Washington, NC 27889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

32 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

47 Total Publications

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 15, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Misbah U. Qadir
Hematology | Oncology
Expertise in
34
conditions
Dr. Misbah U. Qadir
Hematology | Oncology
Referral may be required

ECU Health Cancer Care - Eddie And Jo Allison Smith Tower At ECU Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (0.1 miles away)
252-816-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Misbah Qadir is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina. Dr. Qadir is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Endoscopy. Dr. Qadir is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (0.1 miles away)
252-816-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Knupp is a Hematologist practicing medicine in Greenville, North Carolina. Dr. Knupp is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Thrombotic Thrombocytopenic Purpura, Hereditary Hemorrhagic Telangiectasia, Bone Marrow Aspiration, and Vitrectomy. Dr. Knupp is currently accepting new patients.

Expertise in
5
conditions
Dr. Beng R. Fuh
Hematology | Oncology
Expertise in
5
conditions
Dr. Beng R. Fuh
Hematology | Oncology
Referral may be required

Maynard Children's Hospital At ECU Health Medical Center

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.3 miles away)
252-816-3714
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Beng Fuh is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina. Dr. Fuh is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Fuh is currently accepting new patients.

Frequently Asked Questions about Dr. Darla K. Liles

How do I make an appointment with Dr. Darla K. Liles?

You can book an appointment with Dr. Darla K. Liles by calling their office at 252-816-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Darla K. Liles a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Darla K. Liles is classified as an Elite expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Darla K. Liles specialize in?

While Dr. Darla K. Liles is a Hematology, they have specific expertise in Sickle Cell Disease, Hemoglobinopathy, and Autoimmune Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Darla K. Liles participate in research or clinical trials?

Yes. Dr. Darla K. Liles has published 47 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Darla K. Liles's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Darla K. Liles accept my insurance?

Dr. Darla K. Liles accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 252-816-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liles's expertise for a condition
ConditionClose
View All 34 Advanced Conditions
View All 59 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile